<DOC>
	<DOCNO>NCT02841865</DOCNO>
	<brief_summary>The Response Evaluation Criteria Solid Tumors ( RECIST ) , base difference tumor size , consider reproducible method facilitates measurement mass evaluation response give treatment ; classic chemotherapy induces reduction tumor , new target therapy frequently produce stabilization disease delay progression . These new therapeutic alternative shade light limitation RECIST criterion , since response type treatment basically associate change radiological characteristic tumor , well finding functional imaging . This study aim compare response rate accord Choi RECIST criterion .</brief_summary>
	<brief_title>Evaluation Radiological Response Pancreatic Neuroendocrine Tumors : Comparison Between Choi RECIST Criteria</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<criteria>Patients pancreatic neuroendocrine tumor Ki67 index &lt; 20 % , accept participate sign consent form . In case death patient , waiver consent consider . Patients , accord daily clinical practice , treat sunitinib February 2012 end inclusion period , follow least 6 month . Patients baseline image study ( TC arterial phase ) , least , 6months followup evaluation . Patients progression exitus first image evaluation include . Patients followup &lt; 6months cause beyond progression disease exitus . Patients without baseline radiological evaluation 3/6 month . Patients accept participate study . Patients antiangiogenic treatment within 3 month prior start sunitinib treatment . Patients treat sunitinib plus antiproliferative agent beyond ASS .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>